Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 253 across all filing types
Latest filing 2020-11-16 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samjin Pharmaceutical Co., Ltd. for the 3rd quarter of 2020. It contains detailed financial statements, management discussion and analysis, and operational data, which fits the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act (Article 147). It details the shareholding status of a major shareholder (Choi Sung-ju) and their special related parties in Samjin Pharmaceutical Co., Ltd., including changes in shareholding and collateral agreements. This corresponds to the 'Major Shareholding Notification' category.
2020-10-30 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). This is a standard disclosure document filed with financial regulators (Financial Services Commission and Korea Exchange) to notify the market of changes in significant ownership. It fits the definition of a 'Major Shareholding Notification'.
2020-10-06 Korean
[기재정정]감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Samjin Pharmaceutical regarding the submission of an audit report. It specifically details a correction (amendment) to a previously filed audit report, providing updated financial figures (assets, liabilities, profit/loss) for the 2019 fiscal year. Since it is a formal regulatory disclosure of audit results and corrections rather than the full annual report itself, it falls under the Audit Report/Information category. FY 2019
2020-09-28 Korean
[기재정정]사업보고서 (2019.12)
Annual Report Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a previously filed Annual Report (사업보고서). It explicitly lists the original filing date (2020-03-30) and details specific corrections made to financial tables, including balance sheets, income statements, and cash flow statements due to accounting errors. Since it contains substantive financial data and is a formal amendment to an annual report, it is classified as an Annual Report (10-K) filing type, as it serves as the corrected version of the annual financial disclosure. FY 2019
2020-09-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and major contracts (such as collateral agreements) of a major shareholder and their special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2020-08-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.